Tech Company Financing Transactions
Pep2Tango Therapeutics Funding Round
Pep2Tango Therapeutics, based in Potomac, secured investment capital from Versant Ventures.
Transaction Overview
Company Name
Announced On
11/22/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to develop its novel unimolecular tetra-receptor agonist peptides to treat obesity and related conditions.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
12050 Wetherfield Lane
Potomac, MD 20854
USA
Potomac, MD 20854
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Pep2Tango Therapeutics is a biotech company developing superior unimolecular multi-receptor agonists for obesity and related disorders. Their lead program in obesity is a first-in-class tetra-receptor peptide agonist peptide that shows superiority to Tirzepatide for weight loss in obesity animal models. Other key product differentiation attributes include selective weight loss from fat mass with preservation of lean mass / muscle. With their cutting-edge peptide platform and promising pipeline, Pep2Tango aims to revolutionize obesity and metabolic disease treatment with better, safer, and more effective therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cristina Rondinone
Browse more venture capital transactions:
Prev: 11/22/2024: Empyrean Solutions venture capital transaction
Next: 11/22/2024: KMS Technology venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to document tech company VC transactions. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs